Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...
RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.
NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.B9uuF-Zi.js ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback